VAXESS NAMED 2023 VACCINE INNOVATION OF THE YEAR

BioTech Breakthrough Awards recognizes Vaxess’s sustained release vaccine patch technology

CAMBRIDGE, Mass., November 8, 2023 — Vaxess Technologies, Inc, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, today announced that it has been named “Vaccine Innovation of the Year” in the 2023 BioTech Breakthrough Awards. 

The BioTech Breakthrough Awards highlights breakthrough products, solutions and companies within the life sciences and biotechnology markets. Vaxess was recognized as “Vaccine Innovation of the Year” for the progress the company made developing the MIMIX vaccine patch — the only vaccine patch featuring dissolvable, sustained-release micro tips that can “mimic” the pace of natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response. 

Recently, Vaxess announced that it is collaborating with AstraZeneca for the evaluation of an RNA-based pandemic influenza prototype vaccine in patch format. Earlier in 2023, Vaxess announced mRNA stability results from tests assessing the potential for room-temperature storage. The testing found that Vaxess’s silk fibroin formulations protect mRNA lipid nanoparticles (LNPs) through drying and maintain in vivo potency after storage at 37°C for two weeks, a significant improvement over existing products which require frozen storage.

Additionally, in 2023 Vaxess became the first company to complete a phase 1 trial of a vaccine patch with dissolvable microneedles. The trial, conducted in 45 healthy patients, evaluated delivery of an H1N1 influenza antigen from GC Biopharma Corp., delivered via the Vaxess MIMIX™ Patch. 180-day data showed the influenza vaccine patch elicited strong immune responses and was well-tolerated amongst volunteers.

“Today, more than 1.5 million people globally die each year from diseases for which there is a safe and effective vaccine,” said Michael Schrader, CEO and co-founder of Vaxess. “At Vaxess, we’re focused on making vaccines dramatically more accessible. Our shelf-stable vaccine patch technology has the potential to be distributed without the need for cold storage, and to increase vaccination rates amongst individuals with needle-phobia.” 

Read more about all of the 2023 Biotech Breakthrough Awards recipients here: https://biotechbreakthroughawards.com/2023-winners/.

About Vaxess Technologies

Vaxess Technologies is developing the MIMIX™ sustained release patch technology, the easiest and most effective way to administer vaccines and therapeutics. For vaccines, the controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, ultimately boosting a vaccine’s effectiveness while improving tolerability. Engineered for stability, Vaxess’s patch does not require refrigeration and can be shipped to and applied in low resource settings.

Vaxess has raised grant and venture capital funding from groups such as RA Capital Management, The Engine, BARDA, DARPA, NIH, NSF and the Gates Foundation. For more information, please visit the company website at www.vaxess.com or send additional inquiries to contact@vaxess.com.